# Official Journal C 463/2021

| | ISSN 1977-091X |
| --- | --- |
| Official Journal
  of the European Union | C 463 |
| | |
| English edition | Information and Notices | Volume 6416 November 2021 |

ISSN 1977-091X

Official Journal

of the European Union

C 463

English edition

Information and Notices

Volume 6416 November 2021

---

| Contents | page |
| --- | --- |
| | II   Information |
| | INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2021/C 463/01 | Non-opposition to a notified concentration (Case M.10141 – SANACORP PHARMAHANDEL / LEOPOLD FIEBIG AND GERDA NÜCKEL) (
  1
  ) | 1 |
| 2021/C 463/02 | Non-opposition to a notified concentration (Case M.10097 – AMD / XILINX) (
  1
  ) | 2 |
| 2021/C 463/03 | Non-opposition to a notified concentration (Case M.10490 – BAIN CAPITAL / CTI / BBG HOLDING) (
  1
  ) | 3 |
| 2021/C 463/04 | Non-opposition to a notified concentration (Case M.10184 – CHANNEL 5 / BBC / ITV / CHANNEL 4 / DIGITAL UK) (
  1
  ) | 4 |
| 2021/C 463/05 | Non-opposition to a notified concentration (Case M.10479 – TELENET / WILLEMEN GROEP / LIVIT) (
  1
  ) | 5 |
| 2021/C 463/06 | Non-opposition to a notified concentration (Case M.10466 – GOLDMAN SACHS / ENEOS / NIPPO) (
  1
  ) | 6 |

Contents

page

II   Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2021/C 463/01

Non-opposition to a notified concentration (Case M.10141 – SANACORP PHARMAHANDEL / LEOPOLD FIEBIG AND GERDA NÜCKEL) (
  1
  )

1

1

2021/C 463/02

Non-opposition to a notified concentration (Case M.10097 – AMD / XILINX) (
  1
  )

1

2

2021/C 463/03

Non-opposition to a notified concentration (Case M.10490 – BAIN CAPITAL / CTI / BBG HOLDING) (
  1
  )

1

3

2021/C 463/04

Non-opposition to a notified concentration (Case M.10184 – CHANNEL 5 / BBC / ITV / CHANNEL 4 / DIGITAL UK) (
  1
  )

1

4

2021/C 463/05

Non-opposition to a notified concentration (Case M.10479 – TELENET / WILLEMEN GROEP / LIVIT) (
  1
  )

1

5

2021/C 463/06

Non-opposition to a notified concentration (Case M.10466 – GOLDMAN SACHS / ENEOS / NIPPO) (
  1
  )

1

6

---

| | IV   Notices |
| --- | --- |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | Council |
| 2021/C 463/07 | Notice for the attention of persons subject to the restrictive measures provided for in Council Decision 2013/255/CFSP, as implemented by Council Implementing Decision (CFSP) 2021/1984, and in Council Regulation (EU) No 36/2012, as implemented by Council Implementing Regulation (EU) 2021/1983, concerning restrictive measures in view of the situation in Syria | 7 |
| 2021/C 463/08 | Notice for the attention of the data subjects to whom the restrictive measures provided for in Council Decision 2013/255/CFSP and in Council Regulation (EU) No 36/2012 concerning restrictive measures in view of the situation in Syria apply | 9 |
| | European Commission |
| 2021/C 463/09 | Euro exchange rates — 15 November 2021 | 10 |
| 2021/C 463/10 | Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  ) | 11 |
| 2021/C 463/11 | Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  ) | 12 |
| 2021/C 463/12 | Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  ) | 13 |
| 2021/C 463/13 | Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  ) | 14 |
| 2021/C 463/14 | Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  ) | 15 |
| 2021/C 463/15 | Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  ) | 16 |
| 2021/C 463/16 | Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  ) | 17 |
| 2021/C 463/17 | Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  ) | 18 |

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

Council

2021/C 463/07

Notice for the attention of persons subject to the restrictive measures provided for in Council Decision 2013/255/CFSP, as implemented by Council Implementing Decision (CFSP) 2021/1984, and in Council Regulation (EU) No 36/2012, as implemented by Council Implementing Regulation (EU) 2021/1983, concerning restrictive measures in view of the situation in Syria

7

2021/C 463/08

Notice for the attention of the data subjects to whom the restrictive measures provided for in Council Decision 2013/255/CFSP and in Council Regulation (EU) No 36/2012 concerning restrictive measures in view of the situation in Syria apply

9

European Commission

2021/C 463/09

Euro exchange rates — 15 November 2021

10

2021/C 463/10

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  )

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006

1

11

2021/C 463/11

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  )

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006

1

12

2021/C 463/12

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  )

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006

1

13

2021/C 463/13

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  )

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006

1

14

2021/C 463/14

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  )

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006

1

15

2021/C 463/15

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  )

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006

1

16

2021/C 463/16

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  )

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006

1

17

2021/C 463/17

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
  (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006)
   (
  1
  )

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006

1

18

---

| | V   Announcements |
| --- | --- |
| | ADMINISTRATIVE PROCEDURES |
| | European Commission |
| 2021/C 463/18 | DISCLOSURE OF THE MATERIAL PARTS OF THE BANKRUPTCY DECISION AND INSOLVENCY DECLARATION IN RESPECT OF THE ASSETS OF ČESKOSLOVENSKÉ ÚVĚRNÍ DRUŽSTVO [CZECHOSLOVAK CREDIT UNION] (IN LIQUIDATION) | 19 |
| | PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY |
| | European Commission |
| 2021/C 463/19 | Prior notification of a concentration (Case M.10503 – SK Capital Partners / Seqens) (
  1
  ) | 22 |
| | OTHER ACTS |
| | European Commission |
| 2021/C 463/20 | Publication of an application for registration of a name pursuant to Article 50(2)(a) of Regulation (EU) No 1151/2012 of the European Parliament and of the Council on quality schemes for agricultural products and foodstuffs | 24 |

V   Announcements

ADMINISTRATIVE PROCEDURES

European Commission

2021/C 463/18

DISCLOSURE OF THE MATERIAL PARTS OF THE BANKRUPTCY DECISION AND INSOLVENCY DECLARATION IN RESPECT OF THE ASSETS OF ČESKOSLOVENSKÉ ÚVĚRNÍ DRUŽSTVO [CZECHOSLOVAK CREDIT UNION] (IN LIQUIDATION)

ČESKOSLOVENSKÉ ÚVĚRNÍ DRUŽSTVO

19

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

2021/C 463/19

Prior notification of a concentration (Case M.10503 – SK Capital Partners / Seqens) (
  1
  )

1

22

OTHER ACTS

European Commission

2021/C 463/20

Publication of an application for registration of a name pursuant to Article 50(2)(a) of Regulation (EU) No 1151/2012 of the European Parliament and of the Council on quality schemes for agricultural products and foodstuffs

24

---

| | |
| --- | --- |
| | (1)   Text with EEA relevance. |

---

(1)   Text with EEA relevance.

1

| EN | |
| --- | --- |

EN

---

II Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

| 16.11.2021 | EN | Official Journal of the European Union | C 463/1 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/1

---

Non-opposition to a notified concentration

(Case M.10141 – SANACORP PHARMAHANDEL / LEOPOLD FIEBIG AND GERDA NÜCKEL)

(Text with EEA relevance)

(2021/C 463/01)

On 8 March 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10141. EUR-Lex is the online point of access to European Union law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10141. EUR-Lex is the online point of access to European Union law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 16.11.2021 | EN | Official Journal of the European Union | C 463/2 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/2

---

Non-opposition to a notified concentration

(Case M.10097 – AMD / XILINX)

(Text with EEA relevance)

(2021/C 463/02)

On 30 June 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10097. EUR-Lex is the online point of access to European Union law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10097. EUR-Lex is the online point of access to European Union law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 16.11.2021 | EN | Official Journal of the European Union | C 463/3 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/3

---

Non-opposition to a notified concentration

(Case M.10490 – BAIN CAPITAL / CTI / BBG HOLDING)

(Text with EEA relevance)

(2021/C 463/03)

On 14 October 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10490. EUR-Lex is the online point of access to European Union law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10490. EUR-Lex is the online point of access to European Union law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 16.11.2021 | EN | Official Journal of the European Union | C 463/4 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/4

---

Non-opposition to a notified concentration

(Case M.10184 – CHANNEL 5 / BBC / ITV / CHANNEL 4 / DIGITAL UK)

(Text with EEA relevance)

(2021/C 463/04)

On 13 October 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10184. EUR-Lex is the online point of access to European Union law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10184. EUR-Lex is the online point of access to European Union law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 16.11.2021 | EN | Official Journal of the European Union | C 463/5 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/5

---

Non-opposition to a notified concentration

(Case M.10479 – TELENET / WILLEMEN GROEP / LIVIT)

(Text with EEA relevance)

(2021/C 463/05)

On 4 November 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10479. EUR-Lex is the online point of access to European Union law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10479. EUR-Lex is the online point of access to European Union law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 16.11.2021 | EN | Official Journal of the European Union | C 463/6 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/6

---

Non-opposition to a notified concentration

(Case M.10466 – GOLDMAN SACHS / ENEOS / NIPPO)

(Text with EEA relevance)

(2021/C 463/06)

On 10 November 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10466. EUR-Lex is the online point of access to European Union law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10466. EUR-Lex is the online point of access to European Union law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

Council

| 16.11.2021 | EN | Official Journal of the European Union | C 463/7 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/7

---

Notice for the attention of persons subject to the restrictive measures provided for in Council Decision 2013/255/CFSP, as implemented by Council Implementing Decision (CFSP) 2021/1984, and in Council Regulation (EU) No 36/2012, as implemented by Council Implementing Regulation (EU) 2021/1983, concerning restrictive measures in view of the situation in Syria

(2021/C 463/07)

The following information is brought to the attention of the persons that appear in Annex I to Council Decision 2013/255/CFSP (1), as implemented by Council Implementing Decision (CFSP) 2021/1984 (2), and in Annex II to Council Regulation (EU) No 36/2012 (3), as implemented by Council Implementing Regulation (EU) 2021/1983 (4), concerning restrictive measures in view of the situation in Syria.

The Council of the European Union has decided that those persons should be included in the list of persons and entities in Annex I to Decision 2013/255/CFSP and Annex II to Regulation (EU) No 36/2012. The grounds for designation of those persons appear in the relevant entries in those Annexes.

The attention of the persons concerned is drawn to the possibility of making an application to the competent authorities of the relevant Member State(s) as indicated on the websites in Annex III to Regulation (EU) No 36/2012, in order to obtain an authorisation to use frozen funds for basic needs or specific payments (cf. Article 16 of the Regulation).

The persons concerned may submit a request to the Council, together with supporting documentation that the decision to include them on the above-mentioned list should be reconsidered, before 1 March 2022, to the following address:

| Council of the European Union |
| --- |
| General Secretariat |
| RELEX.1.C |
| Rue de la Loi/Wetstraat 175 |
| 1048 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

Council of the European Union

General Secretariat

RELEX.1.C

Rue de la Loi/Wetstraat 175

1048 Bruxelles/Brussel

BELGIQUE/BELGIË

Email: sanctions@consilium.europa.eu

Any observations received will be taken into account for the purpose of the Council’s next review, pursuant to Article 34 of Decision 2013/255/CFSP and Article 32(4) of Regulation (EU) No 36/2012, of the list of designated persons and entities.

The attention of the persons concerned is also drawn to the possibility of challenging the Council’s decision before the General Court of the European Union, in accordance with the conditions laid down in Article 275, second paragraph, and Article 263, fourth and sixth paragraphs, of the Treaty on the Functioning of the European Union.

---

(1)  OJ L 147, 1.6.2013, p. 14.

(2)  OJ L 402 I, 15.1.2021, p. 5.

(3)  OJ L 16, 19.1.2012, p. 1.

(4)  OJ L 402 I, 15.1.2021, p. 1.

---

| 16.11.2021 | EN | Official Journal of the European Union | C 463/9 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/9

---

Notice for the attention of the data subjects to whom the restrictive measures provided for in Council Decision 2013/255/CFSP and in Council Regulation (EU) No 36/2012 concerning restrictive measures in view of the situation in Syria apply

(2021/C 463/08)

The attention of data subjects is drawn to the following information in accordance with Article 16 of Regulation (EU) 2018/1725 of the European Parliament and of the Council (1).

The legal basis for this processing operation are Council Decision 2013/255/CFSP (2), as implemented by Council Implementing Decision (CFSP) 2021/1984 (3), and Regulation (EU) No 36/2012, as implemented by Council Implementing Regulation (EU) 2021/1983 (4).

The controller of this processing operation is the Council of the European Union represented by the Director General of RELEX (Foreign Affairs, Enlargement, Civil Protection) of the General Secretariat of the Council and the department entrusted with the processing operation is RELEX.1.C that can be contacted at:

| Council of the European Union |
| --- |
| General Secretariat |
| RELEX.1.C |
| Rue de la Loi/Wetstraat 175 |
| 1048 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

Council of the European Union

General Secretariat

RELEX.1.C

Rue de la Loi/Wetstraat 175

1048 Bruxelles/Brussel

BELGIQUE/BELGIË

Email: sanctions@consilium.europa.eu

The purpose of the processing operation is the establishment and updating of the list of persons subject to restrictive measures in accordance with Decision 2013/255/CFSP, as implemented by Council Implementing Decision (CFSP) 2021/1984, and Regulation (EU) No 36/2012, as implemented by Council Implementing Regulation (EU) 2021/1983.

The data subjects are the natural persons who fulfil the listing criteria as laid down in Decision 2013/255/CFSP and Regulation (EU) No 36/2012.

The personal data collected includes data necessary for the correct identification of the person concerned, the statement of reasons and any other data related thereto.

The personal data collected may be shared as necessary with the European External Action Service and the Commission.

Without prejudice to restrictions pursuant to Article 25 of Regulation (EU) 2018/1725, the exercise of the rights of the data subjects such as the right of access, as well as the rights to rectification or to object will be answered in accordance with Regulation (EU) 2018/1725.

Personal data will be retained for 5 years from the moment the data subject has been removed from the list of persons subject to the restrictive measures or the validity of the measure has expired, or for the duration of court proceedings in the event they had been started.

Without prejudice to any judicial, administrative or non-judicial remedy, data subjects may lodge a complaint with the European Data Protection Supervisor in accordance with Regulation (EU) 2018/1725.

---

(1)  OJ L 295, 21.11.2018, p. 39.

(2)  OJ L 147, 1.6.2013, p. 14.

(3)  OJ LI 402, 15.11.2021, p. 5.

(4)  OJ LI 402, 15.11.2021, p. 1.

---

European Commission

| 16.11.2021 | EN | Official Journal of the European Union | C 463/10 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/10

---

Euro exchange rates (1)

15 November 2021

(2021/C 463/09)

1 euro =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,1444 |
| JPY | Japanese yen | 130,32 |
| DKK | Danish krone | 7,4375 |
| GBP | Pound sterling | 0,85165 |
| SEK | Swedish krona | 10,0070 |
| CHF | Swiss franc | 1,0533 |
| ISK | Iceland króna | 150,40 |
| NOK | Norwegian krone | 9,9173 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 25,217 |
| HUF | Hungarian forint | 365,98 |
| PLN | Polish zloty | 4,6374 |
| RON | Romanian leu | 4,9496 |
| TRY | Turkish lira | 11,4643 |
| AUD | Australian dollar | 1,5537 |
| CAD | Canadian dollar | 1,4334 |
| HKD | Hong Kong dollar | 8,9156 |
| NZD | New Zealand dollar | 1,6174 |
| SGD | Singapore dollar | 1,5457 |
| KRW | South Korean won | 1 350,36 |
| ZAR | South African rand | 17,3545 |
| CNY | Chinese yuan renminbi | 7,3034 |
| HRK | Croatian kuna | 7,5128 |
| IDR | Indonesian rupiah | 16 225,69 |
| MYR | Malaysian ringgit | 4,7624 |
| PHP | Philippine peso | 57,309 |
| RUB | Russian rouble | 82,8109 |
| THB | Thai baht | 37,428 |
| BRL | Brazilian real | 6,2458 |
| MXN | Mexican peso | 23,5097 |
| INR | Indian rupee | 85,1430 |

Currency

Exchange rate

USD

US dollar

1,1444

JPY

Japanese yen

130,32

DKK

Danish krone

7,4375

GBP

Pound sterling

0,85165

SEK

Swedish krona

10,0070

CHF

Swiss franc

1,0533

ISK

Iceland króna

150,40

NOK

Norwegian krone

9,9173

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

25,217

HUF

Hungarian forint

365,98

PLN

Polish zloty

4,6374

RON

Romanian leu

4,9496

TRY

Turkish lira

11,4643

AUD

Australian dollar

1,5537

CAD

Canadian dollar

1,4334

HKD

Hong Kong dollar

8,9156

NZD

New Zealand dollar

1,6174

SGD

Singapore dollar

1,5457

KRW

South Korean won

1 350,36

ZAR

South African rand

17,3545

CNY

Chinese yuan renminbi

7,3034

HRK

Croatian kuna

7,5128

IDR

Indonesian rupiah

16 225,69

MYR

Malaysian ringgit

4,7624

PHP

Philippine peso

57,309

RUB

Russian rouble

82,8109

THB

Thai baht

37,428

BRL

Brazilian real

6,2458

MXN

Mexican peso

23,5097

INR

Indian rupee

85,1430

---

(1)  Source: reference exchange rate published by the ECB.

---

| 16.11.2021 | EN | Official Journal of the European Union | C 463/11 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/11

---

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1))

(Text with EEA relevance)

(2021/C 463/10)

Decision granting an authorisation

| Reference of the decision (2) | Date of decision | Substance name | Holder of the authorisation | Authorisation number | Authorised use | Date of expiry
  of review period | Reasons for the decision |
| --- | --- | --- | --- | --- | --- | --- | --- |
| C(2021)7882 | 9 November 2021 | 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated
  (4-tert-OPnEO)
  EC No: -, CAS No:- | Novo Nordisk A/S, Novo Alle, 2880 Bagsværd, Denmark | REACH/21/11/0 | As a solvent/detergent agent for virus inactivation in the manufacture of pharmaceutical products used in the treatment of rare bleeding disorders | 4 January 2033 | In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health from the uses of the substance and there are no suitable alternative substances or technologies. |

Reference of the decision (2)

Date of decision

Substance name

Holder of the authorisation

Authorisation number

Authorised use

Date of expiry

of review period

Reasons for the decision

C(2021)7882

9 November 2021

4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated

(4-tert-OPnEO)

EC No: -, CAS No:-

Novo Nordisk A/S, Novo Alle, 2880 Bagsværd, Denmark

REACH/21/11/0

As a solvent/detergent agent for virus inactivation in the manufacture of pharmaceutical products used in the treatment of rare bleeding disorders

4 January 2033

In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health from the uses of the substance and there are no suitable alternative substances or technologies.

---

(1)  OJ L 396, 30.12.2006 , p. 1.

(2)  The decision is available on the European Commission website at: Authorisation (europa.eu)

---

| 16.11.2021 | EN | Official Journal of the European Union | C 463/12 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/12

---

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1))

(Text with EEA relevance)

(2021/C 463/11)

Decision granting an authorisation

| Reference of the decision (2) | Date of decision | Substance name | Holder of the authorisation | Authorisation number | Authorised use | Date of expiry of review period | Reasons for the decision |
| --- | --- | --- | --- | --- | --- | --- | --- |
| C(2021) 7883 | 9 November 2021 | 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated
  (4-tert-OPnEO)
  EC No: -, CAS No:- | Ortho-Clinical Diagnostics France, 8 Rue Rouget de l’Isle, 92130 Issy-les-Moulineaux, France | REACH/21/6/0 | As Triton X-100 in two in vitro diagnostic VITROS® products used by professional diagnostic laboratories to detect antibodies to human hepatitis A virus and IgG antibodies to rubella virus | 4 January 2031 | In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the use of the substance and there are no suitable alternative substances or technologies. |

Reference of the decision (2)

Date of decision

Substance name

Holder of the authorisation

Authorisation number

Authorised use

Date of expiry of review period

Reasons for the decision

C(2021) 7883

9 November 2021

4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated

(4-tert-OPnEO)

EC No: -, CAS No:-

Ortho-Clinical Diagnostics France, 8 Rue Rouget de l’Isle, 92130 Issy-les-Moulineaux, France

REACH/21/6/0

As Triton X-100 in two in vitro diagnostic VITROS® products used by professional diagnostic laboratories to detect antibodies to human hepatitis A virus and IgG antibodies to rubella virus

4 January 2031

In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the use of the substance and there are no suitable alternative substances or technologies.

---

(1)  OJ L 396, 30.12.2006 , p. 1.

(2)  The decision is available on the European Commission website at: Authorisation (europa.eu)

---

| 16.11.2021 | EN | Official Journal of the European Union | C 463/13 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/13

---

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1))

(Text with EEA relevance)

(2021/C 463/12)

Decision granting an authorisation

| Reference of the decision (2) | Date of decision | Substance name | Holder of the authorisation | Authorisation number | Authorised use | Date of expiry of review period | Reasons for the decision |
| --- | --- | --- | --- | --- | --- | --- | --- |
| C(2021) 7875 | 9 November 2021 | 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated (4-tert-OPnEO) EC No: -, CAS No:- | Nuova Ompi S.r.l. Unipersonale, Via Molinella 17, 35017 Piombino Dese (PD), Italy | REACH/21/8/0 | As emulsifier in the siliconisation of glass containers used as primary packaging for one specific medicinal product NeoRecormon® of one pharmaceutical company | 4 January 2026 | In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the use of the substance and there are no suitable alternative substances or technologies. |

Reference of the decision (2)

Date of decision

Substance name

Holder of the authorisation

Authorisation number

Authorised use

Date of expiry of review period

Reasons for the decision

C(2021) 7875

9 November 2021

4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated (4-tert-OPnEO) EC No: -, CAS No:-

Nuova Ompi S.r.l. Unipersonale, Via Molinella 17, 35017 Piombino Dese (PD), Italy

REACH/21/8/0

As emulsifier in the siliconisation of glass containers used as primary packaging for one specific medicinal product NeoRecormon® of one pharmaceutical company

4 January 2026

In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the use of the substance and there are no suitable alternative substances or technologies.

---

(1)  OJ L 396, 30.12.2006 , p. 1.

(2)  The decision is available on the European Commission website at: Authorisation (europa.eu)

---

| 16.11.2021 | EN | Official Journal of the European Union | C 463/14 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/14

---

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1))

(Text with EEA relevance)

(2021/C 463/13)

Decision granting an authorisation

| Reference of the decision (2) | Date of decision | Substance name | Holder of the authorisation | Authorisation number | Authorised use | Date of expiry of review period | Reasons for the decision |
| --- | --- | --- | --- | --- | --- | --- | --- |
| C(2021) 7874 | 9 November 2021 | 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated
  (4-tert-OPnEO)
  EC No: -, CAS No:- | Janssen Vaccines & Prevention B.V., Archimedesweg 4, 2333 CN Leiden, Netherlands | REACH/21/4/0 | Lysing agent for the permeabilisation of the host cell membrane to release adenovirus particles used for the manufacture of vaccines, allowing the selective elimination of enveloped adventitious viruses, compatible with the chemicals needed to control the host cell DNA precipitation in the next process step | 4 January 2033 | In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the uses of the substance and there are no suitable alternative substances or technologies. |
| Janssen Biologics B.V. Einsteinweg 101, 2333 CB Leiden, Netherlands | REACH/21/4/1 |

Reference of the decision (2)

Date of decision

Substance name

Holder of the authorisation

Authorisation number

Authorised use

Date of expiry of review period

Reasons for the decision

C(2021) 7874

9 November 2021

4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated

(4-tert-OPnEO)

EC No: -, CAS No:-

Janssen Vaccines & Prevention B.V., Archimedesweg 4, 2333 CN Leiden, Netherlands

REACH/21/4/0

Lysing agent for the permeabilisation of the host cell membrane to release adenovirus particles used for the manufacture of vaccines, allowing the selective elimination of enveloped adventitious viruses, compatible with the chemicals needed to control the host cell DNA precipitation in the next process step

4 January 2033

In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the uses of the substance and there are no suitable alternative substances or technologies.

Janssen Biologics B.V. Einsteinweg 101, 2333 CB Leiden, Netherlands

REACH/21/4/1

---

(1)  OJ L 396, 30.12.2006 , p. 1.

(2)  The decision is available on the European Commission website at: Authorisation (europa.eu)

---

| 16.11.2021 | EN | Official Journal of the European Union | C 463/15 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/15

---

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1))

(Text with EEA relevance)

(2021/C 463/14)

Decision granting an authorisation

| Reference of the decision (2) | Date of decision | Substance name | Holder of the authorisation | Authorisation number | Authorised use | Date of expiry of review period | Reasons for the decision |
| --- | --- | --- | --- | --- | --- | --- | --- |
| C(2021) 7876 | 9 November 2021 | 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated
  (4-tert-OPnEO)
  EC No: -, CAS No:- | Abbott Diagnostics GmbH, Max Planck Ring 2, D-65205 Delkenheim, Germany | REACH/21/10/0 | Professional use as a surfactant, in wash buffer components used in conjunction with Fluorescence In Situ Hybridisation (FISH) test kits and/or their Laboratory Developed Test (LDT) equivalents in clinical diagnostic use for medical analysis of human tissue and blood samples to identify characteristic genetic abnormalities related to specific disease conditions | 4 January 2028 | In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the use of the substance and there are no suitable alternative substances or technologies. |

Reference of the decision (2)

Date of decision

Substance name

Holder of the authorisation

Authorisation number

Authorised use

Date of expiry of review period

Reasons for the decision

C(2021) 7876

9 November 2021

4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated

(4-tert-OPnEO)

EC No: -, CAS No:-

Abbott Diagnostics GmbH, Max Planck Ring 2, D-65205 Delkenheim, Germany

REACH/21/10/0

Professional use as a surfactant, in wash buffer components used in conjunction with Fluorescence In Situ Hybridisation (FISH) test kits and/or their Laboratory Developed Test (LDT) equivalents in clinical diagnostic use for medical analysis of human tissue and blood samples to identify characteristic genetic abnormalities related to specific disease conditions

4 January 2028

In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the use of the substance and there are no suitable alternative substances or technologies.

---

(1)  OJ L 396, 30.12.2006 , p. 1.

(2)  The decision is available on the European Commission website at: Authorisation (europa.eu)

---

| 16.11.2021 | EN | Official Journal of the European Union | C 463/16 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/16

---

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1))

(Text with EEA relevance)

(2021/C 463/15)

Decision granting an authorisation

| Reference of the decision (2) | Date of decision | Substance name | Holders of the authorisation | Authorisation number | Authorised use | Date of expiry
  of review period | Reasons for the decision |
| --- | --- | --- | --- | --- | --- | --- | --- |
| C(2021) 7877 | 9 November 2021 | 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated
  (4-tert-OPnEO)
  EC No: -, CAS No:- | Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Strasse 173, 55216, Ingelheim am Rhein, Germany; | REACH/21/7/0 | In a washing buffer to purify biological APIs (active pharmaceutical ingredients) during the production of Palivizumab and Moxetumomab pasudotox-tdfk | 4 January 2033 | In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the uses of the substance and there are no suitable alternative substances or technologies. |
| Boehringer Ingelheim RCV GmbH & Co KG, Dr.-Boehringer-Gasse 5-11, 1121 Wien, Austria. | REACH/21/7/1 |

Reference of the decision (2)

Date of decision

Substance name

Holders of the authorisation

Authorisation number

Authorised use

Date of expiry

of review period

Reasons for the decision

C(2021) 7877

9 November 2021

4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated

(4-tert-OPnEO)

EC No: -, CAS No:-

Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Strasse 173, 55216, Ingelheim am Rhein, Germany;

REACH/21/7/0

In a washing buffer to purify biological APIs (active pharmaceutical ingredients) during the production of Palivizumab and Moxetumomab pasudotox-tdfk

4 January 2033

In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the uses of the substance and there are no suitable alternative substances or technologies.

Boehringer Ingelheim RCV GmbH & Co KG, Dr.-Boehringer-Gasse 5-11, 1121 Wien, Austria.

REACH/21/7/1

---

(1)  OJ L 396, 30.12.2006 , p. 1.

(2)  The decision is available on the European Commission website at: Authorisation (europa.eu)

---

| 16.11.2021 | EN | Official Journal of the European Union | C 463/17 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/17

---

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1))

(Text with EEA relevance)

(2021/C 463/16)

Decision granting an authorisation

| Reference of the decision (2) | Date of decision | Substance name | Holder of the authorisation | Authorisation number | Authorised use | Date of expiry of review period | Reasons for the decision |
| --- | --- | --- | --- | --- | --- | --- | --- |
| C(2021) 7884 | 9 November 2021 | 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated
  (4-tert-OPnEO)
  EC No: -, CAS No:- | Vetter Pharma-Fertigung GmbH & Co. KG, Schuetzenstrasse 87, 88212 Ravensburg, Germany | REACH/21/9/0 | As emulsifier in the siliconisation of glass containers used as primary packaging for two specific medicinal products (NutropinAq® and Lucentis®) of one pharmaceutical company. | 4 January 2026 | In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the use of the substance and there are no suitable alternative substances or technologies. |

Reference of the decision (2)

Date of decision

Substance name

Holder of the authorisation

Authorisation number

Authorised use

Date of expiry of review period

Reasons for the decision

C(2021) 7884

9 November 2021

4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated

(4-tert-OPnEO)

EC No: -, CAS No:-

Vetter Pharma-Fertigung GmbH & Co. KG, Schuetzenstrasse 87, 88212 Ravensburg, Germany

REACH/21/9/0

As emulsifier in the siliconisation of glass containers used as primary packaging for two specific medicinal products (NutropinAq® and Lucentis®) of one pharmaceutical company.

4 January 2026

In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the use of the substance and there are no suitable alternative substances or technologies.

---

(1)  OJ L 396, 30.12.2006 , p. 1.

(2)  The decision is available on the European Commission website at: Authorisation (europa.eu)

---

| 16.11.2021 | EN | Official Journal of the European Union | C 463/18 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/18

---

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1))

(Text with EEA relevance)

(2021/C 463/17)

Decision granting an authorisation

| Reference of the decision (2) | Date of decision | Substance name | Holder of the authorisation | Authorisation number | Authorised use | Date of expiry of review period | Reasons for the decision |
| --- | --- | --- | --- | --- | --- | --- | --- |
| C(2021) 7881 | 9 November 2021 | 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated
  (4-tert-OPnEO)
  EC No: -, CAS No:- | BioMarin International Limited, Shanbally P43 R298, Ringaskiddy, Cork, Ireland | REACH/21/5/0 | Industrial use as a surfactant to perform viral inactivation of biological proteins in the manufacture of a biopharmaceutical Final Bulk Drug Substance (FBDS) for an Enzyme Replacement Therapy (BMN250) for the treatment of Mucopolysaccharidosis IIIB (MPS IIIB) | 4 January 2033 | In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the uses of the substance and there are no suitable alternative substances or technologies. |
| REACH/21/5/1 | Industrial use as a surfactant to perform viral inactivation of biological proteins in the manufacture of a biopharmaceutical Final Bulk Drug Substance (FBDS) for Gene Therapy products for the treatment of rare conditions in the human population |

Reference of the decision (2)

Date of decision

Substance name

Holder of the authorisation

Authorisation number

Authorised use

Date of expiry of review period

Reasons for the decision

C(2021) 7881

9 November 2021

4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated

(4-tert-OPnEO)

EC No: -, CAS No:-

BioMarin International Limited, Shanbally P43 R298, Ringaskiddy, Cork, Ireland

REACH/21/5/0

Industrial use as a surfactant to perform viral inactivation of biological proteins in the manufacture of a biopharmaceutical Final Bulk Drug Substance (FBDS) for an Enzyme Replacement Therapy (BMN250) for the treatment of Mucopolysaccharidosis IIIB (MPS IIIB)

4 January 2033

In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the uses of the substance and there are no suitable alternative substances or technologies.

REACH/21/5/1

Industrial use as a surfactant to perform viral inactivation of biological proteins in the manufacture of a biopharmaceutical Final Bulk Drug Substance (FBDS) for Gene Therapy products for the treatment of rare conditions in the human population

---

(1)  OJ L 396, 30.12.2006 , p. 1.

(2)  The decision is available on the European Commission website at: Authorisation (europa.eu)

---

V Announcements

ADMINISTRATIVE PROCEDURES

European Commission

| 16.11.2021 | EN | Official Journal of the European Union | C 463/19 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/19

---

DISCLOSURE OF THE MATERIAL PARTS OF THE BANKRUPTCY DECISION AND INSOLVENCY DECLARATION IN RESPECT OF THE ASSETS OF ČESKOSLOVENSKÉ ÚVĚRNÍ DRUŽSTVO [CZECHOSLOVAK CREDIT UNION] (IN LIQUIDATION)

(2021/C 463/18)

Výzva k přihlášení pohledávky. Dodržte lhůty!

Výzva k předložení námitek ohledně pohledávky. Dodržte lhůty!

Invitation to lodge a claim. Time limits to be observed.

Invitation to oppose a claim. Time limits to be observed.

Покана за предявяване на вземания. Срокове, които трябва да бъдат спазени.

Покана за подаване на възражения по вземания. Срокове, които трябва да бъдат спазени.

Opfordring til anmeldelse af fordringer. Angivne frister skal overholdes.

Opfordring til at indgive bemærkninger til en fordring. Angivne frister skal overholdes.

Aufforderung zur Anmeldung einer Forderung. Fristen beachten!

Aufforderung zur Erläuterung einer Forderung. Fristen beachten!

Πρόσκληση για αναγγελία απαιτήσεως. Τηρητέες προθεσμίες.

Πρόσκληση υποβολής παρατηρήσεων για απαίτηση. Τηρητέες προθεσμίες.

Convocatoria para la presentación de créditos. ¡Plazos imperativos!

Convocatoria para la presentación de observaciones sobre créditos. ¡Plazos imperativos!

Kutse nõude esitamiseks. Kehtestatud tähtaegadest tuleb kinni pidada.

Kutse nõude vaidlustamiseks. Kehtestatud tähtaegadest tuleb kinni pidada.

Kehotus saatavan ilmoittamiseen. Noudatettavat määräajat.

Kehotus esittää saatavaa koskevia huomautuksia. Noudatettavat määräajat.

Invitation á produire une créance. Délais á respecter!

Invitation á présenter les observations relatives á une créance. Délais á respecter!

Poziv na prijavu tražbine. Rokovi kojih se treba pridržavati.

Poziv na osporavanje tražbine. Rokovi kojih se treba pridržavati.

Felhívás követelés benyújtására. Betartandó határidők.

Felhívás követelés megtámadására. Betartandó határidők.

Invito all’insinuazione di un credito. Termini da osservare.

Invito all’insinuazione di un credito. Termini da osservare.

Siūlymas pateikti reikalavimą. Reikalavimo pateikimo terminai.

Kvietimas paprieštarauti reikalavimui. Prieštaravimo pateikimo terminai.

Uzaicinājums iesniegt prasījumu. Termiņš, kas jāievēro.

Uzaicinājums apstrīdēt prasījumu. Termiņš, kas jāievēro.

Stedina għal preżentazzjoni ta’ talba. Termini li għandhom ikunu osservati.

Stedina għal oppożizzjoni ta’ talba. Termini li għandhom ikunu osservati.

Oproep tot indiening van schuldvorderingen. Let u op de termijn!

Oproep tot het maken van opmerkingen bij schuldvorderingen. Let u op de termijn!

Zaproszenie do wniesienia roszczenia. Obowiązują limity czasowe.

Zaproszenie do zgłaszania uwag dotyczących roszczeń. Obowiązują limity czasowe.

Aviso de reclamação de créditos. Prazos legais a observar!

Aviso de oposição a uma reclamação de créditos. Prazos legais a observar!

Invitație de a prezenta o creanță. Termenele trebuie respectate.

Invitație de a se opune unei creanțe. Termenele trebuie respectate.

Výzva na prihlásenie pohľadávky. Dodržte lehoty!

Výzva na predloženie námietok k pohľadávke. Dodržte lehoty!

Vabilo k prijavi terjatve. Roki, ki jih je treba spoštovati.

Vabilo k zavrnitvi terjatve. Roki, ki jih je treba spoštovati.

Anmodan att anmäla fordran. Tidsfrister.

Anmodan att motsätta sig en fordran. Tidsfrister.

Identification of the debtor:
  Československé úvěrní družstvo [Czechoslovak Credit Union] (in liquidation), Company ID No: 649 46 851, having its registered office at Gočárova třída 312/52, Pražské Předměstí, 500 02 Hradec Králové, entered in the business register held by the Hradec Králové Regional Court under reference 1358 (hereinafter ‘the debtor’)

Identification of the insolvency court and seat of the court: Hradec Králové Regional Court, having its seat at Československé armády 218, 500 03 Hradec Králové (hereinafter ‘the insolvency court’)

Identification of the liquidator: Lukáš Vlašaný, liquidator, having his registered office at Vančurova 2904, 390 01 Tábor, Company ID No: 698 13 019 (hereinafter ‘the liquidator’)

By means of this extract (hereinafter ‘the extract’) the liquidator, within the meaning of Section 370 of Act No 182/2006 on bankruptcy and procedures for handling it (Insolvency Act), as amended (hereinafter ‘the Insolvency Act’), gives notification that the insolvency court has, pursuant to Czech law, established the insolvency of the debtor and declared bankruptcy in respect of the debtor’s assets, by means of a resolution of the Hradec Králové Regional Court of 19 October 2021, ref. KSHK 35 INS 16182/2021-A-34/celk. 5.

Claims by creditors as shown in the debtor’s accounts shall be considered lodged. Creditors shall be notified individually of this fact within 60 days of the insolvency declaration.

Creditors having their registered office, head office, domicile or habitual residence in a Member State of the European Union or of the European Economic Area shall be sent notification in Czech by the liquidator, in accordance with Section 373(2) of the Insolvency Act (hereinafter ‘the notification’).

Any creditor wishing to contest the amount or the nature of his or her claim as stated in the notification may, within four months of the date of the insolvency declaration (i.e. by 21 February 2022), lodge an objection in writing with the liquidator. Failure to do so shall imply the creditor’s agreement with the contents of the notification. Within three months of publication of this extract of the decision to declare insolvency in the Official Journal of the European Union, a creditor may lodge an objection to the effect that he or she has not received a notification from the liquidator. The objection shall state the amount of the claim against the debtor at the date of the insolvency declaration in respect of the debtor’s assets. The objection shall be accompanied by officially certified copies of any documentation confirming the alleged amount, the date of onset and the nature of the claim, and in particular whether the claim is one against the insolvency estate (Section 168 of the Insolvency Act), is equivalent to one against the insolvency estate (Section 169 of the Insolvency Act), is a claim with entitlement to satisfaction from collateral security, is a claim otherwise secured, or is a subsidiary claim (Section 172(2) of the Insolvency Act), and shall state any reservation of title.

Creditors having their registered office, head office, domicile or habitual residence in a Member State of the European Union or of the European Economic Area may, under Section 373(4) of the Insolvency Act, lodge an objection in an official language of that State. In the case referred to in the first sentence of Section 373(4) of the Insolvency Act, the objection must be headed ‘Podání námitky proti výši pohledávky’ [Submission of an objection to the amount of a claim] in Czech. In the case referred to in the second sentence of Section 373(4) of the Insolvency Act, the objection must be headed ‘Přihláška pohledávky’ [Declaration of claim] in Czech. If the content of the objection is clear to the liquidator, he shall take it into account, even if it does not bear the required header. The liquidator shall not be obliged to take a subsequent objection into account, unless it is clear that it was delivered in good time to the authority responsible for serving it. The liquidator may require a creditor to submit a translation of the objection into Czech.

Lukáš Vlašaný, liquidator

Československé úvěrní družstvo [Czechoslovak Credit Union] (in liquidation)

---

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

| 16.11.2021 | EN | Official Journal of the European Union | C 463/22 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/22

---

Prior notification of a concentration

(Case M.10503 – SK Capital Partners / Seqens)

(Text with EEA relevance)

(2021/C 463/19)

1.

This notification concerns the following undertakings:

| — | SK Capital Partners, LP (‘SK Capital Partners’, US), |
| --- | --- |

—

SK Capital Partners, LP (‘SK Capital Partners’, US),

| — | Seqens Group Holding SAS (‘Seqens’, France). |
| --- | --- |

—

Seqens Group Holding SAS (‘Seqens’, France).

SK Capital Partners acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Seqens.

The concentration is accomplished by way of purchase of shares.

2.

| — | SK Capital Partners is a private investment firm focused on specialty materials, chemicals and the pharmaceutical sector; |
| --- | --- |

—

SK Capital Partners is a private investment firm focused on specialty materials, chemicals and the pharmaceutical sector;

| — | Seqens is active in the manufacturing and distribution of diversified essential chemicals, pharmaceutical solutions and specialty ingredients. |
| --- | --- |

—

Seqens is active in the manufacturing and distribution of diversified essential chemicals, pharmaceutical solutions and specialty ingredients.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10503 – SK Capital Partners / Seqens

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---

OTHER ACTS

European Commission

| 16.11.2021 | EN | Official Journal of the European Union | C 463/24 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/24

---

Publication of an application for registration of a name pursuant to Article 50(2)(a) of Regulation (EU) No 1151/2012 of the European Parliament and of the Council on quality schemes for agricultural products and foodstuffs

(2021/C 463/20)

This publication confers the right to oppose the application pursuant to Article 51 of Regulation (EU) No 1151/2012 of the European Parliament and of the Council (1) within three months from the date of this publication.

SINGLE DOCUMENT

’Zagorski bagremov med’

EU No: PDO-HR-02612 – 1 June 2020

PDO (X) PGI ( )

1.   Name(s) [of PDO or PGI]

’Zagorski bagremov med’

2.   Member State or Third Country

Republic of Croatia

3.   Description of the agricultural product or foodstuff

3.1.   
  Type of product

Class 1.4 Other products of animal origin (eggs, honey, various dairy products except butter, etc.)

3.2.   
  Description of the product to which the name in (1) applies

3.2.1.   Definition of the product

‘Zagorski bagremov med’ is produced from the nectar of acacia (Robinia pseudoacacia), as the predominant plant species, and from concomitant melliferous plants from the Hrvatsko Zagorje region. The region’s specific geomorphological and climatic conditions influenced the emergence of the concomitant plant species, which, together with the main plant species, affect the botanical origin of the honey. The product is placed on the market in the form of extracted honey, comb honey, or extracted honey with cut comb.

3.2.2.   Pollen characteristics

In addition to the pollen of acacia (Robinia pseudoacacia), pollen of the following nectar plant species may also be present in the pollen spectrum of ‘Zagorski bagremov med’: common dogwood (Cornus sanguinea), alder buckthorn (Frangula alnus), European loranth (Loranthus europaeus), plants of the composite family (Asteraceae), maple (Acer spp.), red clover (Trifolium pratense), dandelion (Taraxacum officinale), plants of the crucifer family (Brassicaceae), fruit species (Prunus spp.), plants of the dandelion-type composite family (Asteraceae: Taraxacum type), plants of the umbellifer family (Apiaceae), mustards (Sinapis spp.), lime (Tilia spp.), birdsfoot trefoil (Lotus corniculatus), knapweed (Centaurea spp.), and the pollen of other plant species in smaller proportions. Pollen of the following non-nectar plant species may also be present in the pollen spectrum: ash (Fraxinus spp.), cocksfoot (Dactylis glomerata), plants of the grass family (Poaceae), plantain (Plantago spp.), meadow-sweet (Filipendula spp.), sedge (Carex spp.), oak (Quercus spp.) and poppy (Papaver spp.).

When the pollen content of non-nectar plant species in ‘Zagorski bagremov med’ is deducted from the total amount of pollen, more than 27 % must be acacia (Robinia pseudoacacia) pollen.

3.2.3.   Organoleptic characteristics

‘Zagorski bagremov med’ has the following organoleptic characteristics:

Appearance

Colour: very light, ranging from near-colourless, through light- to straw-yellow, depending how unifloral the honey sample is.

Clearness: extremely clear.

Crystallisation: it remains in a liquid state for a long time, rarely crystallising.

Odour

Not intense, and may have a discernible odour of acacia flower and fresh wax, depending how unifloral the honey sample is.

Taste

Medium to very sweet, with low acidity.

Flavour

Short- to medium-lasting flavour of vanilla, acacia flower, virgin honeycomb and fresh butter.

3.2.4.   Physical-chemical parameters

Water content: not more than 18,0 %.

Electrical conductivity: not more than 0,25 mS/cm.

Hydroxymethylfurfural (HMF) content: not more than 15 mg/kg of honey.

3.3.   
  Feed (for products of animal origin only) and raw materials (for processed products only)

It is forbidden to feed bee colonies while the bees are pasturing.

3.4.   
  Specific steps in production that must take place in the identified geographical area

All steps in the production of ‘Zagorski bagremov med’ (pasturing and extraction) must take place in the geographical area defined in point 4.

3.5.   
  Specific rules concerning slicing, grating, packaging, etc. of the product the registered name refers to

To ensure the quality and traceability of the product, ‘Zagorski bagremov med’ must be packaged in the defined geographical area. During transport, unsuitable (high) temperatures may alter the physico-chemical parameters and organoleptic characteristics of ‘Zagorski bagremov med’, or may cause the honey to take on undesirable extraneous odours or attract moisture from the air. For that reason, hermetic lids are used for packaging the honey, and the use of metal lids is recommended.

For packaging the honey, packages of different sizes are used, depending on market conditions, and a corresponding record is kept.

3.6.   
  Specific rules concerning labelling of the product the registered name refers to

Before being placed on the market, all packaging must bear the special ‘Zagorski bagremov med’ logo, which must be larger than the other inscriptions on the packaging. The graphic representation of the logo consists of a black background, with the text ZAGORSKI BAGREMOV MED in the middle, the words ‘zagorski’ and ‘med’ in white and the word ‘bagremov’ in yellow. To the left of the text are three stylised white bees of various sizes (Figure 1).

Image 1

Figure 1 The ‘Zagorski bagremov med’ logo

4.   Concise definition of the geographical area

The geographical area of production of ‘Zagorski bagremov med’ comprises the Hrvatsko Zagorje region, more specifically: Krapina-Zagorje County in its entirety; the western part of Varaždin County, which includes the towns and municipalities of Bednja, Lepoglava, Ivanec, Novi Marof, Breznički Hum and Breznica; and the edge of Zagreb County bordering Krapina-Zagorje and Varaždin Counties, which includes the municipalities of Brdovec, Marija Gorica, Pušća, Dubravica, Luka, Jakovlje, Bistra and Bedenica and the settlements of Kupljenovo, Bregovljana, Hruševec Kupljenski and Pojatno.

5.   Link with the geographical area

Specificity of the geographical area

Natural vegetation and extensive agriculture characterise most of the Hrvatsko Zagorje region, which has little intensive agricultural production or industry. The geographical area defined in point 4 therefore offers optimal conditions for the development of beekeeping.

The specificity of ‘Zagorski bagremov med’ is largely determined by topographical and climatic factors and the floral resources of the defined geographical area.

The defined geographical area has a humid continental-type climate. Winter is relatively mild, summer moderately warm, autumn slightly warmer than spring, and the mean values of both transitional seasons exceed the mean annual temperature. Late autumn and winter are often warmer and sunnier on the hills than on the plains. The valleys frequently experience frost, which the hills are spared. Hrvatsko Zagorje has a continental precipitation pattern, with frequent, heavy rain in May, June and July, i.e. during the vegetation period. November sees another peak in precipitation, while February and March see the least precipitation. Annual precipitation is around 1 000 mm. Winds are modified by the hilly terrain. Westerly winds are the most frequent, lasting for 45 % of the year, followed by easterly winds, which last for 29 % of the year, while around 6 % of the year is wind-free. The maximum wind strength ranges from force 6 to force 9, the strongest winds occurring from late autumn to early spring (Crkvenčić et al, 1974b, in: Geografija SR Hrvatske [Geography of the Socialist Republic of Croatia], pp. 69-81).

One specific and recognisable feature of Hrvatsko Zagorje is its multitude of hills, which spare the acacia stands any late-spring frost. The hilly terrain also allows the acacia to flower – and the bees to pasture – for longer, since the acacia flowers first in protected lower-lying areas before flowering at higher altitudes. While bees pasture on acacia for an average of around 10-12 days on the plains of Croatia, in the defined geographical area the configuration of the land extends this to 20 days (Šimić, 1980, in: Naše medonosno bilje [Our Melliferous Plants], pp. 84 and 85).

The climate conditions of the defined geographical area greatly influence the secretion of nectar. According to Farkas and Zajacz (2007) (Nectar Production for the Hungarian Honey Industry, p. 134), the optimal conditions for the secretion of acacia nectar are no wind, warm nights (around 15 °C) with sufficient morning dew, and moderately warm days with a daytime temperature of 25 °C. Approximate values as regards air temperature were confirmed in a study by Krušelj conducted over a three-year period during the flowering of acacia in Krapina-Zagorje County (2012 PhD dissertation Utjecaj vremenskih i proizvodnih uvjeta na kakvoću bagremova meda s područja Krapinsko-zagorske županije [Influence of Weather and Production Conditions on the Quality of Acacia Honey from Krapina-Zagorje County], pp. 66, 77 and 81).

The specificity of the defined geographical area is also reflected in its floral resources, i.e. the presence of acacia stands, most of which occur in groups or are mixed with other tree species. As a highly reproductive plant, acacia spreads easily, rapidly occupying moist, fertile soil, and can act as a pioneer species.

The defined geographical area has a centuries-old tradition of beekeeping, which was one of the main agricultural activities on the manors and estates of Zagorje. Honey and wax were some of the most sought-after products on the market. That is why, as early as 1626, the Croatian Parliament (Petrić, 2011, in: Samobor i okolica u ranom novom vijeku [Samobor and Environs during the Early Modern Period], pp. 309-310 and F. Šišić, 1918, in: Podatci o skladištima meda [Data on Honey Warehouses], Croatian Parliamentary Records, pp. 458, 465) decreed that honey could be exported only from the towns of Krapina, Varaždin and Samobor (Mudrinjak, 2017, in: Hrvatska pčela [The Croatian Honey Bee], pp. 203-205). The honey exported from Croatia had to be weighed, and 2 Kreuzer were paid for each 100 kg of honey weighed.

Specificity of the product

The presence of pollen grains from the plant species present in the production area makes it possible to determine both the geographical and the botanical origin of the honey. According to the results of pollen analyses of numerous studies, the minimum 20 % acacia pollen grains required to declare a honey variety unifloral rises to 27 % for ‘Zagorski bagremov med’. The decidedly unifloral character of this honey is reflected in its physico-chemical properties (electrical conductivity) and the expressiveness of its organoleptic characteristics, highlighting its specificity and distinctiveness compared with samples of the same type of honey from other regions. Moreover, even after years of evaluating acacia honey from the defined geographical area, monitoring of the botanical origin of its samples has shown no trace of pollen from oilseed rape. This highlights the region’s specificity compared with most other parts of Croatia where acacia honey can be produced.

Causal link between the specificity of the geographical area and the specificity of the product

The topographical and climatic factors and the floral resources of the defined geographical area for the production of ‘Zagorski bagremov med’ determine its specificity. The configuration of the land (hilly terrain) of Hrvatsko Zagorje influences the duration of flowering of the acacia and, therefore, the pasturing of the bees, which it extends to 20 days. At the same time, due to the properties of the soil (heavier, acidic soils), the small, fragmented parcels of land, and the difficulty implementing agricultural techniques, there is no tradition of growing oilseed rape, which makes the defined geographical area specifically suited to the production of ‘Zagorski bagremov med’ compared with other parts of Croatia where acacia honey is produced in areas planted with oilseed rape and it is impossible to avoid the presence of the nectar (and, therefore, pollen) of oilseed rape.

The specificity of ‘Zagorski bagremov med’ is based on the long-established tradition of beekeeping, so that the link with the defined geographical area is also reflected in historical, traditional and cultural elements.

One of the main historical links with the production of honey and wax in Hrvatsko Zagorje is the production of liticar [a sweet honey dough biscuit, like gingerbread] and candles. The gingerbread craft arrived in this region at the turn of the 16th and 17th centuries through trade routes as part of the Styrian Liticar Makers’ Guild, and it remains here to this day. The gingerbread craft in Hrvatsko Zagorje was recognised and entered on UNESCO’s Representative List of the Intangible Cultural Heritage of Humanity in 2010.

The high quality of production of ‘Zagorski bagremov med’ is the product of the skills acquired by beekeepers from Hrvatsko Zagorje in contemporary technological approaches to rearing bee colonies and in the preparation of the honey for the market. These beekeepers pay particular attention to finding the best locations for both stationary and nomadic apiaries, and to timely extraction, which is a prerequisite for the production of quality honey.

For the past 16 years, Krapina-Zagorje County and the Federation of Beekeeping Associations of Krapina-Zagorje County have organised an event promoting the quality of ‘Zagorski bagremov med’ and beekeepers from Zagorje, at which honey from Krapina-Zagorje County is showcased and judged.

As proof of the specificity of ‘Zagorski bagremov med’ compared with acacia honey from other parts of Croatia, an acacia honey sample of one beekeeper from Konjščina in Hrvatsko Zagorje was declared the best in the world at the Apimedica and Apiquality Forum held in Ljubljana in 2010. In addition to this success, ‘Zagorski bagremov med’ from the defined geographical area has continuously ranked high at honey-judging events held in Croatia and nearby Slovenia for many years now.

Reference to publication of the specification

(the second subparagraph of Article 6(1) of this Regulation)

https://poljoprivreda.gov.hr/UserDocsImages/dokumenti/hrana/zoi-zozp-zts/dokumenti-zoi-zozp-zts/Specifikacija_proizvoda_Zagorski_bagremov_med.pdf

---

(1)  OJ L 343, 14.12.2012, p. 1.

---